Cargando…

Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development

Detalles Bibliográficos
Autores principales:	Subramaniam, Sriram, Shord, Stacy S., Leong, Ruby, Norsworthy, Kelly, Rahman, Atiqur, Booth, Brian, Okusanya, Olanrewaju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176012/ https://www.ncbi.nlm.nih.gov/pubmed/36823411 http://dx.doi.org/10.1111/cts.13496

Ejemplares similares

US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer
por: Shord, Stacy S., et al.
Publicado: (2023)

Lights and Shadows in Immuno-Oncology Drug Development
por: Bergamino Sirvén, Milana, et al.
Publicado: (2021)

Machine learning approaches to predict drug efficacy and toxicity in oncology
por: Badwan, Bara A., et al.
Publicado: (2023)

Oncology drug health technology assessment recommendations: Canadian versus UK experiences
por: Chabot, Isabelle, et al.
Publicado: (2014)

Convection and Retro-Convection Enhanced Delivery: Some Theoretical Considerations Related to Drug Targeting
por: Motion, J. P. Michael, et al.
Publicado: (2010)

Long-Acting Injectable Drugs for HIV-1 Pre-Exposure Prophylaxis: Considerations for Africa
por: Moyo, Enos, et al.
Publicado: (2022)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Point-of-care community drug checking technologies: an insider look at the scientific principles and practical considerations
por: Gozdzialski, Lea, et al.
Publicado: (2023)

Considerations and recommendations for assessment of plasma protein binding and drug–drug interactions for siRNA therapeutics
por: Humphreys, Sara C, et al.
Publicado: (2022)

Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology
por: Lythgoe, Mark P., et al.
Publicado: (2022)

Establishing a Multidisciplinary Framework to Study Drug‐Drug Interactions of Hormonal Contraceptives: An Invitation to Collaborate
por: Lesko, Lawrence J., et al.
Publicado: (2018)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Molecular interaction networks and drug development: Novel approach to drug target identification and drug repositioning
por: Loscalzo, Joseph
Publicado: (2022)

Oral Glucose Tolerance Test: An Informative Endpoint or an Added Burden in Metformin Drug–Drug Interaction Studies?
por: Dauki, Anees M., et al.
Publicado: (2022)

The pK(a) Distribution of Drugs: Application to Drug Discovery
por: Manallack, David T.
Publicado: (2007)

Recent drug approvals for acute myeloid leukemia
por: Lai, Catherine, et al.
Publicado: (2019)

Phentermine-topiramate: First combination drug for obesity
por: Singh, Jagjit, et al.
Publicado: (2015)

An open science pathway for drug marketing authorization—Registered drug approval
por: Naudet, Florian, et al.
Publicado: (2021)

Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies
por: Li, Yimei, et al.
Publicado: (2022)

Antifungal Drug Repurposing
por: Kim, Jong H., et al.
Publicado: (2020)

Opportunities and Challenges of Using Big Data to Detect Drug‐Drug Interaction Risk
por: Quinney, Sara K.
Publicado: (2019)

Real world studies are essential for drug therapy in Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

Challenges and opportunities for improving access to approved neonatal drugs and devices
por: Lewis, Tamorah, et al.
Publicado: (2022)

Population Mobility, Globalization, and Antimicrobial Drug Resistance
por: MacPherson, Douglas W., et al.
Publicado: (2009)

Local drug delivery of folic acid promotes oral mucosal wound healing
por: Khan, Saif, et al.
Publicado: (2021)

Drugging SUMOylation for neuroprotection and oncotherapy
por: Bernstock, Joshua D., et al.
Publicado: (2018)

Paramagnetic NMR in drug discovery
por: Softley, Charlotte A., et al.
Publicado: (2020)

Drugs, sleep, and the addicted brain
por: Valentino, Rita J., et al.
Publicado: (2019)

Amorphous Drug-Polymer Salts
por: Yao, Xin, et al.
Publicado: (2021)

Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives
por: Pawełczyk, Anna, et al.
Publicado: (2020)

Low Drug Loading Hampers the Clinical Translation of Peptide Drugs-Containing Metered-Dose Inhalers
por: Huang, Zhengwei, et al.
Publicado: (2022)

Versatile applications of deep eutectic solvents in drug discovery and drug delivery systems: Perspectives and opportunities
por: Hayyan, Maan
Publicado: (2023)

Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development
por: Ahmed, Mariam A., et al.
Publicado: (2019)

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
por: Hobbs, Brian P, et al.
Publicado: (2018)

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
por: Yamazaki, Shinji, et al.
Publicado: (2022)

Pushing the boundaries of behavioral analysis could aid psychiatric drug discovery
por: Sweis, Brian M., et al.
Publicado: (2022)

Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience
por: Villalona-Calero, Miguel A., et al.
Publicado: (2023)

Innovation in Oncology Drug Development
por: Huber, Matthew, et al.
Publicado: (2019)

Perspectives on How to Drug an Ion Channel
por: Andersen, Olaf Sparre
Publicado: (2008)

Comparing Highly Efficacious Antimalarial Drugs
por: Sutherland, Colin J
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_o981hpn5lqh1p55bat3ekla7sa